2136287-59-5Relevant academic research and scientific papers
Pyridone-containing polycyclic derivative inhibitor as well as preparation method and application thereof
-
Paragraph 0163; 0166-0169, (2021/05/12)
The invention relates to a pyridone-containing polycyclic derivative inhibitor as well as a preparation method and an application thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method
Spiro pyridone derivative and application
-
, (2020/12/29)
The invention discloses a spiro pyridone derivative which has a structure shown in a general formula I in the specification. Researches show that the spiro pyridinone derivative has a relatively strong inhibition effect on the activity of influenza A virus RNA polymerase, and can be applied to the preparation of influenza A virus RNA polymerase activity inhibition and influenza A resistance medicines. The general formula I is shown in the specification.
Pyridone [1, 2-b] [1,5] triazepine derivatives as well as preparation and application thereof (by machine translation)
-
, (2020/12/30)
The invention discloses a hydroxypyridone [1, a-b] [1,5] triazepine derivatives as well as preparation and application thereof. Experiments prove that the hydroxypyridinone [1, 2-b] [1,triazepine derivatives (general formula I) have a good inhibition effect on the RNA polymerase activity of influenza A virus RNA, and can be used as an influenza virus RNA polymerase inhibitor to treat influenza caused by influenza virus. General Formula I is as follows. (by machine translation)
PYRIDOPYRAZINE AND PYRIDOTRIAZINE INHIBITORS OF INFLUENZA VIRUS REPLICATION
-
, (2020/05/06)
Provided herein are compounds that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza. (I)
Sulfur-containing heterocyclic compound and preparation method thereof
-
Paragraph 0077-0079, (2020/11/09)
The invention relates to a sulfur-containing heterocyclic compound and a preparation method thereof. Specifically, the invention discloses a preparation method of a compound A. The preparation methodcomprises the following step: in an organic solvent, und
Compound for preparing barocasvir or derivatives thereof as well as preparation method and application of compound
-
Paragraph 0119-0123, (2020/08/18)
The invention relates to a preparation method of a compound represented by a formula 1. The method comprises the following steps that: the compound represented by a formula 2 is prepared by reaction of a compound represented by a formula 3, and then the compound represented by the formula 1 is prepared by reaction of the compound represented by the formula 2, wherein R1 is an amino protecting group, and preferably, the amino protecting group is selected from any one of tert-butyloxycarbonyl, benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl, allyloxycarbonyl, ethoxycarbonyl, trichloroethoxycarbonyl, phthaloyl, triphenylmethyl, p-methoxybenzyl, p-toluenesulfonyl and methoxycarbonyl; and R3 is selected from any one of -CH2OH, an aldehyde group, an ester group, an amide group, a cyano group and acarboxyl group. The method has the advantages of simplicity and convenience in operation, high yield, safety, environmental protection, low cost, suitability for industrial production and the like.
Synthetic method of key intermediate of Xofluza
-
Paragraph 0027; 0034-0038, (2020/12/30)
According to a synthetic method of a key intermediate of Xofluza, the structure of the key intermediate is as shown in the following formulas 1-6, and the synthetic method comprises the following steps: carrying out amine ester exchange reaction on a compound diglycolamine as shown in the following formula I to obtain a compound as shown in the following formula 1-4; carrying out one-step oxidation reaction on the compound shown as the following formula 1-4 to prepare a compound shown as the following formula 1-5; and carrying out Mannich reaction on the compound as shown in the following formula (1-5) under an acidic condition to obtain the key intermediate (1-6) of Xofluza. In the amine ester exchange reaction, a compound 2-(2, 2-dimethoxyethoxy) ethane-1-amine as shown in the followingformula II is not used.
Substituted polycyclic pyridone compound and prodrug thereof
-
Paragraph 0173-0176; 0183; 0184, (2019/10/23)
The invention provides a deuterium-substituted polycyclic pyridone compound, a prodrug thereof, a composition containing the compound and application of the composition. The deuterium-substituted polycyclic pyridone compound is the compound shown in the formula (I) or a tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate or solvent compound thereof. The compound and the composition show the cap-dependent endonuclease inhibitory activity and have superior pharmacokinetic properties.
Substituted polycyclic pyridone derivative and its crystal
-
Paragraph 0041, (2018/06/30)
Substituted polycyclic pyridone derivative of the manufacturing method. Formula (I): (In the formula, R1 Is hydrogen, unsubstituted alkyl or other protecting group. ) Shown in compound, and/or magnesium salt in the presence of a sodium salt, Formula: R2 - OH (In the formula, R2 A non-substituted alkyl. ) Is reacted with a compound represented by the, formula (II): (In the formula, R2 The same significance as described above. ) Production of a compound represented.
